NCT04577716

Brief Summary

The purpose of the study is to describe Sodium Fluoride uptake (using Positron Emission Tomography-Computed Tomography - PET-CT) following Endovascular Aneurysm Repair (EVAR) and to determine whether Sodium Fluoride PET-CT can predict the development of endoleaks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2021

Longer than P75 for all trials

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2020

Completed
22 days until next milestone

First Posted

Study publicly available on registry

October 8, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

April 1, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2025

Completed
Last Updated

July 3, 2025

Status Verified

June 1, 2025

Enrollment Period

4 years

First QC Date

September 16, 2020

Last Update Submit

July 2, 2025

Conditions

Keywords

EVAREndoleak18F-Sodium FluoridePET

Outcome Measures

Primary Outcomes (1)

  • Microcalcification activity in stented and aneurysmal aorta

    Will be measured as 18F Sodium Fluoride binding in the aorta. Uptake will be quantified in Standardised Uptake Values and as a tissue to background ratios.

    12 months

Secondary Outcomes (10)

  • Pattern of microcalcification activity in the stented aorta

    12 months

  • Intensity of microcalcification activity in the stented aorta

    12 months

  • Endoleaks

    12 months

  • Stent graft migration

    12 months

  • Aneurysm sac diameter

    12 months

  • +5 more secondary outcomes

Other Outcomes (1)

  • Co-localisation of 18F-Sodium Fluoride with histological changes in aortic tissue

    12-36 months

Study Arms (3)

Endoleak Group

Participants with a previous Endovascular Aneurysm Repair (EVAR) who have developed an endoleak

Diagnostic Test: 18F Sodium Fluoride Positron Emission Tomography / Computed TomographyDiagnostic Test: CT Aortic Angiogram

No Endoleak Group

Participants with a previous Endovascular Aneurysm Repair (EVAR) who have not developed an endoleak

Diagnostic Test: 18F Sodium Fluoride Positron Emission Tomography / Computed TomographyDiagnostic Test: CT Aortic Angiogram

Pre-EVAR Group

Participants who have an abdominal aortic aneurysm and who are undergoing an Endovascular Aneurysm Repair as standard of care

Diagnostic Test: 18F Sodium Fluoride Positron Emission Tomography / Computed TomographyDiagnostic Test: 12-month CT Aortic AngiogramOther: 24-month review

Interventions

PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan

Endoleak GroupNo Endoleak GroupPre-EVAR Group
CT Aortic AngiogramDIAGNOSTIC_TEST

CT scan to assess aortic morphology and contextualise PET scan

Endoleak GroupNo Endoleak Group

CT scan to assess aortic morphology and the stent graft

Pre-EVAR Group

This will consist of a telephone consultation with the study participant and review of electronic clinical records

Pre-EVAR Group

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study population will consist of individuals with an abdominal aortic aneurysm (AAA). The first part of the study (Study 1 - Case Control Study) will recruit patients with existing EVAR in to two groups: patients that have an endoleak or related complication (endoleak group, n = 22) and those that have remained complication-free (no endoleak group, n = 22). We will also prospectively recruit patients who are yet to receive EVAR or fenestrated EVAR (pre-EVAR group, n = 100) for the (Study 2 - Cohort Study). There will be four patient identification centres from which patients will be recruited: NHS Lothian, NHS Lanarkshire, NHS Greater Glasgow and Clyde, and NHS Tayside.

You may qualify if:

  • A diagnosis of AAA as defined by the European Society of Vascular Surgery guidelines on the management of aorto-iliac artery aneurysms, and having undergone endovascular repair within the recommended Instructions For Use (IFU) by the manufacturer. \['Endoleak' and 'No Endoleak groups only\]
  • Complication will be defined as any type of endoleak or stent graft migration \['Endoleak' group only\].
  • A diagnosis of AAA requiring endovascular repair OR a diagnosis of juxtarenal AAA requiring fenestrated endovascular aneurysm repair as defined by the European Society of Vascular surgery guidelines on the management of aorto-iliac artery aneurysms and planned EVAR or fenestrated EVAR surgery. \['pre-EVAR' group only\]
  • Minimum age: 50 years. No maximum age.
  • Retain capacity for informed consent

You may not qualify if:

  • The inability of patients to undergo PET/CT scanning
  • Chronic kidney disease (eGFR ≤ 30 mL/min/1.73 m2)
  • Major or untreated cancer
  • Pregnancy
  • Allergy or contra-indication to iodinated contrast
  • Inability or unwillingness to give informed consent
  • Life-expectancy of less than two years
  • Known history of connective tissue disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Ninewells Hospital

Dundee, DD2 1SG, United Kingdom

Location

University Hospital Hairmyres

East Kilbride, G75 8RG, United Kingdom

Location

Royal Infirmary of Edinburgh

Edinburgh, EH16 4SB, United Kingdom

Location

Queen Elizabeth University Hospital

Glasgow, G51 4TF, United Kingdom

Location

Related Publications (2)

  • Debono S, Nash J, Fletcher AJ, Syed M, van Beek EJR, Williams MC, Falah O, Tambyraja A, Dweck MR, Newby DE, Forsythe RO. Aortic sodium [18F]fluoride uptake following endovascular aneurysm repair. Heart. 2023 Oct 26;109(22):1677-1682. doi: 10.1136/heartjnl-2023-322514.

  • Debono S, Nash J, Tambyraja AL, Newby DE, Forsythe RO. Endovascular repair for abdominal aortic aneurysms. Heart. 2021 Nov;107(22):1783-1789. doi: 10.1136/heartjnl-2020-318288. Epub 2021 Mar 4.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Aortic tissue specimens obtained from individuals undergoing open surgical repair will be studied histologically, using autoradiography and micro-PET/CT.

MeSH Terms

Conditions

Aortic Aneurysm, AbdominalEndoleak

Interventions

Tomography, X-Ray Computed

Condition Hierarchy (Ancestors)

Aortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic DiseasesPostoperative HemorrhageHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsPostoperative Complications

Intervention Hierarchy (Ancestors)

Image Interpretation, Computer-AssistedDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisRadiographic Image EnhancementImage EnhancementPhotographyRadiographyTomography, X-RayTomography

Study Officials

  • Samuel Debono

    University of Edinburgh

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2020

First Posted

October 8, 2020

Study Start

April 1, 2021

Primary Completion

March 31, 2025

Study Completion

March 31, 2025

Last Updated

July 3, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

There are no plans for individual participant data sharing.

Locations